Asset Details
Do you wish to reserve the book?
Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens
Do you wish to request the book?
Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens
2020
Overview
Flavodoxins are small soluble electron transfer proteins widely present in bacteria and absent in vertebrates. Flavodoxins participate in different metabolic pathways and, in some bacteria, they have been shown to be essential proteins representing promising therapeutic targets to fight bacterial infections. Using purified flavodoxin and chemical libraries, leads can be identified that block flavodoxin function and act as bactericidal molecules, as it has been demonstrated for Helicobacter pylori (Hp), the most prevalent human gastric pathogen. Increasing antimicrobial resistance by this bacterium has led current therapies to lose effectiveness, so alternative treatments are urgently required. Here, we summarize, with a focus on flavodoxin, opportunities for pharmacological intervention offered by the potential protein targets described for this bacterium and provide information on other gastrointestinal pathogens and also on bacteria from the gut microbiota that contain flavodoxin. The process of discovery and development of novel antimicrobials specific for Hp flavodoxin that is being carried out in our group is explained, as it can be extrapolated to the discovery of inhibitors specific for other gastric pathogens. The high specificity for Hp of the antimicrobials developed may be of help to reduce damage to the gut microbiota and to slow down the development of resistant Hp mutants.
Publisher
MDPI AG,MDPI
Subject
Anti-Bacterial Agents - chemical synthesis
/ Anti-Bacterial Agents - chemistry
/ Anti-Bacterial Agents - pharmacology
/ Anti-Bacterial Agents - therapeutic use
/ Bacteria
/ Drug Resistance, Bacterial - drug effects
/ Flavodoxin - antagonists & inhibitors
/ Gastrointestinal Microbiome - drug effects
/ Helicobacter Infections - drug therapy
/ Helicobacter pylori - drug effects
/ Helicobacter pylori - metabolism
/ Humans
/ Non-pharmacological intervention
/ Review
